Protein Synthesis in Normal and Regenerating Liver
Protein Synthesis in Normal and Regenerating Liver
批准号:
8488848
负责人:
DAVID A SHAFRITZ
金额:
$8.76万
依托单位国家:
美国
项目类别:
财政年份:
1977
资助国家:
美国
项目状态:
已结题
起止时间:
1977-05-01 至 2013-06-30
关键词:
AddressAdultAgeAgingApoptosisApoptoticAttentionBile Duct EpitheliumCandidate Disease GeneCell DeathCell LineCell ProliferationCell TransplantationCell TransplantsCellsCharacteristicsChronicClinicalCoupledDissectionDrosophila genusEngraftmentEpithelialEpithelial CellsEventExhibitsFetal LiverGene ExpressionGenesGoalsGrowthHepaticHepatic MassHepatocyteHomologous GeneHumanIndividualInjuryLasersLeadLiverLiver FailureLiver parenchymaMaintenanceMeasuresMethodsMusNatural regenerationPathway interactionsPhenotypeProcessProgenitor Cell EngraftmentProliferatingPropertyProtein BiosynthesisRNARattusResearchReverse Transcriptase Polymerase Chain ReactionRoleSignaling Pathway GeneSiteStagingStem cellsSystemTherapeuticTimeTransplantationWingbasebile ductclinical applicationcytokinedensityfetus cellgenome-widein vivointerestknock-downlaser capture microdissectionliver functionliver growth factorliver transplantationmutantoverexpressionpublic health relevanceresearch studyself-renewalstemsurvivinuptake
中文摘要
描述(由申请人提供):目前,全肝移植是治疗终末期慢性肝衰竭的主要方法。随着可用供体肝脏的显著短缺,人们对鉴定干细胞或祖细胞可以恢复肝脏质量和功能产生了相当大的兴趣。我们已经证明,胎肝上皮细胞可以重新填充高达30%的正常肝脏实质质量,产生新的肝细胞和胆管,并继续增殖长达一年后,细胞移植。这些都是干细胞的特性,我们将这些细胞称为胎肝干/祖细胞(FLSPC)。我们假设使用正常的基于肝脏的细胞移植系统,如我们已经建立的系统,在确定分离的细胞和细胞系的干细胞潜能和鉴定有助于其在肝脏中增殖和分化的基本因子方面是至关重要的。最近,我们发现胎肝细胞通过细胞竞争取代宿主肝细胞,这一过程最初在果蝇中描述。在此背景下,实验提出:1。研究胎肝干/祖细胞植入肝实质是肝再生的限速步骤的假设。这些研究将利用小鼠和大鼠胎肝干/祖细胞,这些细胞已使用免疫磁珠(MACS)纯化至95%同质性。2.研究调节细胞竞争并了解发生这种情况的情况将导致确定移植FLSPC的肝脏重建的最佳条件的假设。繁殖/竞争会持续多久?细胞移植时宿主受体的年龄是否影响再增殖的程度?竞争总是由宿主肝脏中增加的凋亡驱动吗?我们能否在移植前通过敲低FLSPC中抗凋亡基因生存素的表达来阻止肝脏再生?3.确定哺乳动物肝脏再生过程中调节细胞竞争的特定基因、信号通路和机制。我们的假设是,移植FLSPC对宿主肝细胞的竞争优势来自这些细胞中的抗凋亡基因的过表达,再加上通过外源性细胞死亡途径增强宿主肝细胞的凋亡。我们将通过激光捕获显微切割从活跃增殖的移植细胞簇和周围宿主肝脏中分离RNA并通过RT-PCR、qRT-PCR和高密度基因表达微阵列研究特异性基因表达来鉴定所涉及的特异性基因和信号通路,以及4)为了直接证明体内胎肝上皮祖细胞的关键干细胞特性,包括它们克隆生长的能力,他们的双能性和自我更新的能力。这些研究的总体目标是找到通过移植肝源性细胞来增强肝脏再生的方法,最终将导致人类的临床应用。公共卫生相关性:该项目旨在优化成年大鼠肝脏与胎肝干/祖细胞的再增殖,并确定参与细胞竞争的关键步骤,机制和基因,调节这一过程。
英文摘要
DESCRIPTION (provided by applicant): Currently, whole liver transplantation is the primary method used to treat end stage chronic liver failure. With the marked shortage of available donor livers, there has been considerable interest in identifying stem or progenitor cells can restore liver mass and function. We have demonstrated that fetal liver epithelial cells can repopulate up to 30% of parenchymal mass in normal liver, produce new hepatocytes and bile ducts and continue to proliferate for up to one year after cell transplantation. These are all properties of stem cells and we refer to these cells as fetal liver stem/progenitor cells (FLSPC). We hypothesize that use of a normal liver based cell transplantation system, such as the one we have established, is critical in determining the stem cell potential of isolated cells and cell lines and in identifying essential factors that contribute to their proliferation and differentiation in the liver. Recently, we discovered that fetal liver cells replace host hepatocytes by cell competition, a process originally described in Drosophila. Within this context, experiments are proposed: 1. To study the hypothesis that engraftment of fetal liver stem/progenitor cells into the hepatic parenchyma represents a rate limiting step in liver repopulation. These studies will utilize mouse and rat fetal liver stem/progenitor cells that have been purified to 95% homogeneity using immunomagnetic beads (MACS). 2. To study the hypothesis that modulating cell competition and understanding the circumstances under which this occurs will lead to identifying optimal conditions for liver repopulation by transplanted FLSPC. How long does repopulation/competition continue? Does the age of the host recipient at the time of cell transplantation influence the extent of repopulation? Is competition always driven by increased apoptosis in the host liver? and Can we block liver repopulation by knocking down expression of the anti-apoptotic gene, survivin, in FLSPC prior to their transplantation? 3. To identify specific genes, signaling pathways and mechanisms that regulate cell competition during mammalian liver repopulation. Our hypothesis is that the competitive advantage of transplanted FLSPC over host hepatocytes derives from overexpression of anti-apoptotic genes in these cells, coupled with augmented apoptosis of host hepatocytes through the extrinsic cell death pathway. We will identify the specific genes and signaling pathways involved by isolating RNA from actively proliferating transplanted cell clusters and surrounding host liver by laser-capture micro dissection and studying specific gene expression by RT-PCR, qRT-PCR and high density gene expression microarrays and 4) To directly demonstrate critical stem cell properties of fetal liver epithelial progenitor cells in vivo, including their ability to grow clonally, their bipotency and their capacity for self-renewal. The overall goal of these studies is to find methods to enhance liver repopulation by transplanted hepatic derived cells that will ultimately lead to clinical application in humans. Public Health Relevance: This project is directed toward optimizing repopulation of the adult rat liver with fetal liver stem/progenitor cells and in determining the critical steps, mechanism and genes involved in cell competition, which regulates this process.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Changing patterns of transcriptional and post-transcriptional control of liver-specific gene expression during rat development.
大鼠发育过程中肝脏特异性基因表达的转录和转录后控制模式的变化。
DOI:
10.1101/gad.1.10.1172
发表时间:
1987
期刊:
Genes & development
影响因子:
10.5
作者:
[Panduro,A, Shalaby,F, Shafritz,DA]
通讯作者:
Shafritz,DA
Regulation of liver gene expression during various physiologic and pathophysiologic states.
各种生理和病理生理状态下肝脏基因表达的调节。
DOI:
--
发表时间:
1990
期刊:
Progress in liver diseases
影响因子:
--
作者:
[Shafritz,DA]
通讯作者:
Shafritz,DA
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.
DOI:
10.1172/jci17902
发表时间:
2003-07
期刊:
The Journal of clinical investigation
影响因子:
--
作者:
[O. Kollet;Shoham Shivtiel;Yuan-Qing Chen;Jenny Suriawinata;S. Thung;M. Dabeva;J. Kahn;Asaf Spiegel-Asaf-Spie]
通讯作者:
O. Kollet;Shoham Shivtiel;Yuan-Qing Chen;Jenny Suriawinata;S. Thung;M. Dabeva;J. Kahn;Asaf Spiegel-Asaf-Spie
Transcriptional and post-transcriptional control of liver gene expression during various physiologic and pathophysiologic states.
各种生理和病理生理状态下肝脏基因表达的转录和转录后控制。
DOI:
10.1055/s-2008-1040550
发表时间:
1988
期刊:
Seminars in liver disease
影响因子:
4.2
作者:
[Shafritz,DA]
通讯作者:
Shafritz,DA
GENETICALLY MODIFIED HEPATOCYTES TO ACHIEVE SUCCESS IN LIVER CELL TRANSPLANTATION
-
批准号:8762032
-
项目类别:
-
资助金额:$67.07万
-
财政年份:2014
-
负责人:DAVID A SHAFRITZ
-
依托单位:
GENETICALLY MODIFIED HEPATOCYTES TO ACHIEVE SUCCESS IN LIVER CELL TRANSPLANTATION
-
批准号:8921193
-
项目类别:
-
资助金额:$5.58万
-
财政年份:2014
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Pilot and Feasibility Program
-
批准号:8377128
-
项目类别:
-
资助金额:$0.25万
-
财政年份:2012
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Administrative Core and Enrichment Program
-
批准号:8377118
-
项目类别:
-
资助金额:$42.09万
-
财政年份:2012
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Administrative Core and Enrichment Program
-
批准号:8377122
-
项目类别:
-
资助金额:$42.09万
-
财政年份:2012
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Administrative Core and Enrichment Program
-
批准号:7688348
-
项目类别:
-
资助金额:$67.02万
-
财政年份:2009
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Protein Synthesis in Normal and Regenerating Liver
-
批准号:7905579
-
项目类别:
-
资助金额:$9.97万
-
财政年份:2009
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Pilot and Feasibility Program
-
批准号:7688371
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Administrative Core
-
批准号:7499798
-
项目类别:
-
资助金额:$13.72万
-
财政年份:2007
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Administrative Core and Enrichment Program
-
批准号:6797578
-
项目类别:
-
资助金额:$66.41万
-
财政年份:2004
-
负责人:DAVID A SHAFRITZ
-
依托单位:
A NEW MODEL FOR LIVER GENE THERAPY USING THE LIVER
-
批准号:6178142
-
项目类别:
-
资助金额:$31.98万
-
财政年份:1999
-
负责人:DAVID A SHAFRITZ
-
依托单位:
A NEW MODEL FOR LIVER GENE THERAPY USING THE LIVER
-
批准号:6381654
-
项目类别:
-
资助金额:$32.94万
-
财政年份:1999
-
负责人:DAVID A SHAFRITZ
-
依托单位:
A NEW MODEL FOR LIVER GENE THERAPY USING THE LIVER
-
批准号:6011698
-
项目类别:
-
资助金额:$31.05万
-
财政年份:1999
-
负责人:DAVID A SHAFRITZ
-
依托单位:
A NEW MODEL FOR LIVER GENE THERAPY USING THE LIVER
-
批准号:6635195
-
项目类别:
-
资助金额:$34.94万
-
财政年份:1999
-
负责人:DAVID A SHAFRITZ
-
依托单位:
A NEW MODEL FOR LIVER GENE THERAPY USING THE LIVER
-
批准号:6517657
-
项目类别:
-
资助金额:$33.93万
-
财政年份:1999
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Liver Pathobiology and Gene Theraphy Research Core Center
-
批准号:7867965
-
项目类别:
-
资助金额:$124.5万
-
财政年份:1997
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Liver Pathobiology and Gene Theraphy Research Core Center
-
批准号:7867589
-
项目类别:
-
资助金额:$29.25万
-
财政年份:1997
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Liver Pathobiology and Gene Therapy Research Core Center
-
批准号:8277996
-
项目类别:
-
资助金额:$124.5万
-
财政年份:1997
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Liver Pathobiology and Gene Theraphy Research Core Center
-
批准号:7649607
-
项目类别:
-
资助金额:$124.5万
-
财政年份:1997
-
负责人:DAVID A SHAFRITZ
-
依托单位:
Liver Pathobiology and Gene Theraphy Research Core Center
-
批准号:8067840
-
项目类别:
-
资助金额:$122.48万
-
财政年份:1997
-
负责人:DAVID A SHAFRITZ
-
依托单位:
海外基金